Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Fig. 2

Genome-wide LOH in TCGA-BLCA dataset and tumor tissue samples. Each circle represents a tissue sample, and the bars represent the median and interquartile range. Black circles in the ATLAS dataset highlight samples with deleterious alterations in DDR pathway genes BRCA1, BRCA2, PALB2, or RAD51C. DDR DNA damage response; IQR interquartile range; LOH loss of heterozygosity; TCGA-BLCA The Cancer Genome Atlas Urothelial Bladder Carcinoma

Back to article page